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Abstract 
Background 
DNA methylation is an important epigenetic mechanism in several human diseases, most 
notably cancer. The quantitative analysis of DNA methylation patterns has the potential to 
serve as diagnostic and prognostic biomarkers, however, there is currently a lack of 
consensus regarding the optimal methodologies to quantify methylation status. To address 
this issue we compared five analytical methods: (i) MethyLight qPCR, (ii) MethyLight digital 
PCR (dPCR), methylation-sensitive and -dependent restriction enzyme (MSRE/MDRE) 
digestion followed by (iii) qPCR or (iv) dPCR, and (v) bisulfite amplicon next generation 
sequencing (NGS). The techniques were evaluated for linearity, accuracy and precision. 
Results 
Methylight qPCR displayed the best linearity across the range of tested samples. Observed 
methylation measured by Methylight- and MSRE/MDRE-qPCR and -dPCR were not 
significantly different to expected values whilst bisulfite amplicon NGS analysis over-
estimated methylation content. Bisulfite amplicon NGS showed good precision, whilst the 
lower precision of qPCR and dPCR analysis precluded discrimination of differences of <25% 
in methylation status. A novel dPCR Methylight assay is also described as a potential method 
for absolute quantification that simultaneously measures both sense and antisense DNA 
strands following bisulfite treatment. 
Conclusions 
Our findings comprise a comprehensive benchmark for the quantitative accuracy of key 
methods for methylation analysis and demonstrate their applicability to the quantification of 
circulating tumour DNA biomarkers by using sample concentrations that are representative of 
typical clinical isolates. 
Keywords 
DNA methylation, Reference material, Digital PCR, NGS, Quantification 
Background 
The methylation of CpG dinucleotides is a common epigenetic mechanism in eukaryotes that 
plays an essential role in the regulation of gene activity. Defects in methylation have been 
described in several human diseases, most notably cancer (reviewed in [1]). Alterations in the 
methylation status of CpG islands in human cancers can lead to genomic instability and 
silencing of tumour suppressor genes [2-5]. The strong correlation between methylation 
status and cancer development and progression has led to a growing interest in the use of 
methylation markers in circulating DNA for cancer diagnosis and prognosis [6,7]. However, 
in order for such clinical applications to be developed, further work is required to determine 
which are the optimal methodologies to quantify methylation status accurately and 
reproducibly. Indeed, numerous technologies are used for methylation analysis (reviewed in 
[8] and [9]) and many of these have not previously been evaluated in terms of their 
quantitative accuracy, precision and repeatability of measurement. 
The majority of the most commonly used methods for DNA methylation analysis are those 
based on sodium bisulfite conversion or methylation-dependent or -sensitive restriction 
enzymes (defined as MSREs or MDREs respectively throughout). In the first, sodium 
bisulfite is used to hydrolytically deaminate unmethylated cytosine to uracil while leaving 
methylated cytosines unchanged [10-12]. Bisulfite converted DNA can be used to assess 
methylation status by several methods, including PCR and sequencing. Clonal sequencing of 
bisulfite converted DNA is considered to be the ‘gold standard’ for methylation 
quantification, as it allows the high-throughput identification of all the methylated cytosines 
within an extensive region combined with single molecule quantification [13]. The 
development of pyrosequencing and Next Generation Sequencing (NGS) in recent years has 
provided an increased genomic coverage and sequencing depth [14-17]. MethyLight [18,19] 
is one of the most common PCR based approaches; it involves the bisulfite conversion of 
DNA followed by real-time quantitative PCR (qPCR) by using primers and hydrolysis probes 
that are complementary to either the methylated or unmethylated bisulfite-converted DNA 
sequences. The Methylight approach has also been applied to a recently developed 
microfluidic digital PCR platform [20]. Digital PCR (dPCR) involves the distribution of 
samples over hundreds of reaction wells resulting in each well containing either one or no 
template molecules, allowing a digital readout of the number of molecules present in the 
distributed sample, and the absolute quantification of copy number without the need for 
calibration [21,22]. An alternative to the sodium bisulfite conversion based methods are those 
that utilise MSREs and MDREs. One such method involves qPCR amplifying a target region 
spanning several CpG sites that have been digested by one or more MSREs or MDREs [23-
25]. MSREs are unable to digest restriction sites containing methylated cytosine residues, 
whereas MDREs require the presence of methylated DNA to induce strand cleavage. By 
comparison of expression levels with a mock digested template, the relative amounts of 
methylated and unmethylated DNA can be calculated [23,24]. Recent studies have also 
applied RE digestion analysis to dPCR platforms [26,27], with Hindson et al. [26] 
demonstrating a superior precision and sensitivity of measurement compared to qPCR. 
In this study, we investigate the suitability of a range of methods based on bisulfite 
conversion and restriction enzyme digestion for accurate quantification of methylated DNA 
copies. The methylation status of the p14ARF (alternative reading frame) gene was chosen as 
the target for quantification, as it is a putative tumour suppressor gene that has been shown to 
be hypermethylated in human cancers [28-31] and offers potential as a candidate biomarker 
[32-36]. The comparison study was performed using a panel of standards containing a 
mixture of methylated and unmethylated DNA combined in a range of known ratios. We 
analysed quantities of DNA that were representative of clinical samples, such as circulating 
cell free DNA, which is typically present at 103 genomic copies per mL plasma [37], in order 
to make this study relevant to the use of methylation biomarkers in non-invasive diagnosis. 
This material was used to compare restriction enzyme (defined as RE throughout)- and 
Methylight-based analysis using qPCR and dPCR platforms and to evaluate bisulfite 
amplicon NGS. Our findings provide the first comprehensive comparison of these methods 
and we also develop a novel strategy for absolute quantification of methylated DNA by 
Methylight dPCR. 
Results 
To assess the accuracy and precision of DNA methylation quantification technologies, five 
commonly used methods for the quantification of the proportion of methylated DNA 
molecules were investigated by analysing the methylation status of the biomarker, p14ARF, 
with each method targeting the same region of the p14ARF promoter (Additional file 1), using 
a panel of DNA standards combined in a range of methylated and unmethylated ratios. 
Aliquots of a single preparation of this panel were used for analysis by all of the methylation 
quantification methodologies in a series of independent experiments in order to test the 
robustness of the approaches. 
RE digestion qPCR and dPCR quantification 
To evaluate RE digestion based PCR (termed RE digestion (q/d)PCR hereafter) 
quantification of DNA methylation, the panel of methylated/unmethylated DNA standards 
were treated with either MSREs which cleave restriction sites when unmethylated or MDREs 
which induce strand cleavage only in the presence of methylated DNA, in three independent 
experiments replicating the whole process. Both classes of restriction enzyme showed a good 
performance in terms of the efficiency and specificity of digestion. For example, the 0% 
methylated sample treated with MSREs showed no detection of p14 promoter DNA when 
measured either by qPCR or dPCR (Table 1). The 100% methylated sample did not show a 
complete digestion with the MDRE treatment, however only minimal amounts of template 
were present following digestion compared to controls used for normalization (Table 1). 
Table 1 Restriction enzyme qPCR and dPCR 
Expected methylation (%) Average methylation ± standard deviation (%) 
qPCR dPCR 
MDRE MSRE MDRE MSRE 
100 97 ± 1¥ 100 94 ± 6* 100 
90 87 ± 6+ 85 ± 4 86 ± 6 63 ± 12 
75 79 ± 8‡ 69 ± 17 74 ± 13 93 ± 32 
50 42 ± 22¥,+,‡ 36 ± 11*,¥,+ 59 ± 16* 55 ± 11*,¥,+ 
25 25 ± 9 21 ± 4*,‡ 31 ± 17 24 ± 7*,‡ 
10 22 ± 20 7 ± 1¥ 11 ± 28 12 ± 5¥ 
0 0 0+,‡ 0 0+,‡ 
The average % methylation calculated from three independent qPCR and dPCR measurements of a panel of 
methylated/unmethylated DNA standards using Methylation-Dependent Restriction Enzyme (MDRE) and Methylation-
Sensitive Restriction Enzyme (MSRE) treatments; Each PCR measurement was performed using an independent RE 
digestion as template. Data normalised to the 100% methylated sample for MSRE assays and 0% for MDRE assays. 
Statistical comparisons using a One-Way ANOVA were performed on the data where each RE class was used within its 
optimal template range (0-50% for MSRE; 50-100% for MDRE); all comparisons between samples that were significant at 
the level of p < 0.05 are shown with pairs of symbols denoting which two samples were compared, e.g. for MDRE dPCR, 
only the 50 and 100% methylated (expected % methylation) data points were significantly different from each other at the 
level of p < 0.05. Data points that were outside the viable range of the assay (<0% or >100% methylation) were removed 
from the analysis; all experimental conditions were n = 3 with the exception of the following that were n = 2: 25% and 10% 
MDRE qPCR and 90% MSRE qPCR (expected % methylation). 
The average percent methylation measured in all reactions is presented in Table 1 and Figure 
1 (see Materials and Methods for details of percent methylation calculations). Consistent with 
a previous study [23], the data demonstrate how the variability of measurement can increase 
when the REs are used within a range of template % methylation that is not optimal for 
accurate PCR quantification, e.g. standard deviation measurements are generally higher in the 
0-25% methylated template range with the MDRE digestion (Table 1, Figure 1A,C). 
Furthermore, outside the optimal template range, several data points displayed values that 
were outside the feasible range of the assay (<0% or >100% methylation) and therefore were 
removed from the analysis (Table 1 and Figure 1A,B). Therefore, in order to assess the 
accuracy of this method, the correlation between expected and observed percent methylation 
for the data points was analysed where each class of RE was in its optimal range (0-50% 
methylated data points for MDRE and 50-100% methylated for MSRE, Figure 1A-D). Figure 
1 demonstrates that, within the optimal template methylation ranges, both MS- and MDREs 
show a significant correlation with the expected percent methylation for both qPCR and 
dPCR measurements (p = 0.0011 for MDRE dPCR, all others are p < 0.0001) however when 
data from the entire range are included, the correlation between observed and expected values 
generally decreases (data not shown), highlighting the importance of using the digestion 
enzymes within their optimal working range. 
  
Figure 1 Restriction enzyme qPCR and dPCR. Correlation between expected and observed 
percent methylation for MSRE (B,D) and MDRE (A,C) qPCR (A,B) and dPCR (C,D) 
analysis. Correlation performed with samples which comprise the optimal working range of 
the respective enzyme classes: 0-50% for MSRE (B,D) and 50-100% for MDRE (A,C) 
(dotted lines). Data points that were outside the viable range of the assay (<0% or >100% 
methylation) were removed from the analysis. All experimental conditions were n = 3 with 
the exception of the following which were n = 2: 25% and 10% MDRE qPCR and 90% 
MSRE qPCR (expected % methylation). Error bars show ± Standard Deviation of three 
independent replicate measurements. (E) Correlation between Restriction enzyme qPCR vs. 
dPCR measurements using the data points in which the restriction enzymes are within their 
optimal working range. A single outlying data point was removed from the correlation 
analysis. All correlations were significant at p < 0.0001 except for expected vs. MDRE dPCR 
which was p = 0.0011. 
The correlation between the qPCR and dPCR measurements, using the optimal template 
methylation range values, was also significant (R2 = 0.93; p < 0.0001; Figure 1E) however, 
analysis of the standard deviation values (Table 1 and Figure 1) revealed that, in the majority 
of cases, dPCR showed greater variability of measurement between replicates compared to 
qPCR. Precision of measurement was tested by performing a one-way ANOVA statistical 
analysis of the data to determine which observed differences in methylation status were 
statistically significant. This analysis revealed that the RE qPCR approach could accurately 
discriminate differences in ≥25% methylation, however comparisons of 10% and 15% 
differences could not be resolved, indicating that the precision of this method was not 
accurate enough to use for differences of <25% methylation. For RE dPCR, the MSRE 
approach showed a comparable performance to qPCR, with the same comparisons between 
samples showing statistically significant differences. However, the MDRE dPCR approach 
showed poorer precision than MDRE qPCR, with only the 50 vs. 100% methylation 
comparison showing a statistically significant difference (Table 1). 
Methylight qPCR and dPCR analysis 
To analyse and estimate the variation of quantification of methylation by Methylight qPCR 
and dPCR, three independent bisulfite conversions were performed on the panel of 
methylated/unmethylated DNA. The replicates of bisulfite converted DNA were quantified 
by qPCR and dPCR using the same hydrolysis probe assay. Figure 2A and B show that there 
was a strong correlation between the average observed and expected percent methylation 
when measured by qPCR and dPCR across the full range of methylation (p < 0.0001 for all 
correlations). The p14 assays showed a good specificity of measurement for the methylated 
template with both Methylight qPCR and dPCR, as the 0% methylated template was not 
detected by either method with the p14_M assay. 
Figure 2 Methylight qPCR and singleplex dPCR. Correlation between expected and 
observed % methylation for Methylight qPCR (A) and singleplex dPCR (B). using the 
p14_M assay. Error bars show ± Standard Deviation of three independent replicate 
measurements (C).Correlation between Methylight qPCR vs. singleplex dPCR. All 
correlations were significant at p < 0.0001. 
However, the performance of qPCR and dPCR in terms of reproducibility of measurement 
revealed that, in the majority of cases, the standard deviation measurements were higher for 
dPCR compared to qPCR (Table 2). The inferior precision of Methylight dPCR was also 
demonstrated in that qPCR was able to resolve differences in percent methylation of ≥25% 
however none of the statistical comparisons below a 50% difference in methylation were 
significant for Methylight dPCR using the p14_M assay in singleplex (Table 2). 
Table 2 Methylight qPCR and dPCR 
Expected methylation (%) Average methylation ± standard deviation (%) 
qPCR dPCR 
P14_M P14_M P14_M P14_M2 P14_M + P14_M2 
Singleplex Singleplex Duplex Duplex Duplex 
100 100* 100 100 100 100 
90 78 ± 4¥ 77 ± 27 99 ± 19* 86 ± 20 92 ± 19 
75 66 ± 18* 81 ± 13 86 ± 20 77 ± 17 81 ± 19 
50 49 ± 10¥,+ 52 ± 16 58 ± 10*,¥ 57 ± 28* 56 ± 18* 
25 28 ± 4‡ 21 ± 7 31 ± 5 28 ± 2 29 ± 4 
10 13 ± 3+ 17 ± 4 18 ± 6¥ 9 ± 15* 13 ± 10* 
0 0‡ 0 0 0 0 
The average % methylation calculated from three independent qPCR and dPCR measurements of three independent bisulfite 
conversions of a panel of methylated/unmethylated DNA standards; Data for dPCR show measurements from the P14_M 
assay used in singleplex and for the P14_M and P14_M2 assays used together in duplex, showing the % methylation for 
each assay when analysed individually and with the estimated targets combined (P14_M + P14_M2). Symbols denote 
statistical comparisons using a One-Way ANOVA test. All comparisons between samples with expected differences in 
methylation of ≥50 % were significant at the level of p < 0.05 (with the exception of 50 vs. 100% methylation with 
Methylight P14_M2 Duplex) and are not shown; all comparisons between samples of differences between 0-40% expected 
methylation that are significant (p < 0.05) are shown with pairs of the same symbols denoting which two samples were 
compared, e.g. for dPCR P14_M2 duplex, only the 0 and 50% methylated (expected % methylation) data points were 
significantly different from each other at the level of p < 0.05. 
Duplex Methylight dPCR analysis 
A dPCR approach offers the possibility of absolute quantification of methylated DNA 
without a calibration curve [21]. However one source of uncertainty with respect to the 
accuracy of copy number concentration measurements is whether the DNA template is 
present in single-stranded or double-stranded conformation [38]. In the former case 
individual strands of the duplex can become separated into different partitions and be 
amplified, resulting in a ‘double-count’ which could lead to overestimation of template 
concentration under the assumption of double-stranded conformation [38]. We hypothesised 
that this source of uncertainty could be resolved for dPCR analysis of methylated DNA as 
following bisulfite treatment the DNA strands are no longer complementary, enabling each 
strand to be discriminated [13]. In the case of the region targeted in this study, 47% of 
nucleotides within the Methylight p14 assay target region are non-complementary after 
bisulfite conversion of the 100% methylated template and 68% for the 0% methylated 
template. 
An additional MethyLight assay (‘P14_M2’) was designed (Additional file 2) to amplify the 
opposite of the two resultant heteroduplex strands to that targeted by the P14_M assay 
(previous section). To enable the assays to be distinguished, the probe for each assay was 
labelled with a different fluorophore, allowing duplexing of the reaction. The p14_M2 assay 
also showed high specificity for methylated P14 DNA and did not amplify non-methylated 
templates (Figure 3). 
  
Figure 3 Methylight duplex dPCR. (A) Duplex p14 dPCR assay showing data for p14_M 
and p14_M2 assays separately and with estimated targets for both assays combined. (B) 
dPCR heatmap showing distribution of p14_M (red) and p14_M2 (blue) positive chambers in 
a duplex reaction showing three example panels of a dPCR plate. (C) Correlation between 
Methylight qPCR vs. duplex dPCR (estimated targets for both assays combined). All 
correlations were significant at p < 0.0001. 
Figure 3A shows the observed vs. expected percent methylation for the dPCR analysis 
showing the p14_M and p14_M2 primers and probe when used in duplex (data shown for 
each assay individually and when estimated targets from both assays are pooled). The data 
demonstrate that both single- and duplex dPCR assays show a strong correlation with the 
expected values (p < 0.0001). 
The duplex approach to Methylight dPCR demonstrates that amplifications of the two non-
complementary DNA strands (by p14_M and p14_M2 assays) are independently localised, as 
seen in the dPCR heat maps in three example panels (Figure 3B) (<0.02% of positive 
chambers showed amplification with both assays on average over all panels of all 
experiments). This confirms that the starting template is largely in a single-stranded 
conformation and that each assay is specific to either strand of the starting template as non-
specific amplification of the ‘non-template’ strand would have resulted in amplification of 
both assays in a large number of the chambers. Similarly to the singleplex Methylight dPCR 
(Figure 2C), there was a significant correlation between the qPCR and duplex dPCR 
measurements (Figure 3C; p < 0.0001). 
Absolute quantification of restriction digested- and bisulfite-treated DNA 
In order to assess the comparative yield between the bisulfite and RE approaches, the copy 
number obtained from RE dPCR and Methylight dPCR was compared (Figure 4). The DNA 
quantified in our experiments before RE digestion or bisulfite treatment was ~1500 genomic 
copies based on the manufacturer’s specifications of the 100% methylated and unmethylated 
DNA standards. However, our fluorimetric measurements (Qubit) indicated the copy number 
to be ~950 genomic copies (Figure 4). The number of amplifiable copies of the p14 and 
COL2A1 genomic regions detected by MSRE-dPCR, mock digestion conditions and 
Methylight dPCR was less than the values based on Qubit analysis (p < 0.05) with the 
exception of the MDRE-dPCR assay (0% methylated template (p = not significant). No 
significant differences were observed between MSRE or MDRE analysis of their control 
templates (100% and 0% methylated respectively) and mock digest conditions. Likewise, 
comparison of the copy numbers of p14 obtained by Methylight dPCR with those obtained 
for the methylation independent control, COL2A1, in the same sample (100% methylated), 
did not reveal any significant differences (p > 0.05, student’s t-test), indicating a comparable 
efficiency for the p14 and COL2A1 assays, confirming that COL2A1 was a suitable reference 
for the effects of sample processing on the target gene of interest. 
  
Figure 4 Comparison of DNA copy numbers obtained using different techniques. DNA 
copy numbers of methylated/unmethylated DNA standards based on specifications of 
manufacturer (Expected), measured by flourimeter and of p14 by RE and p14 and COL2A1 
with Methylight dPCR in the 0% and 100% methylated samples. Copy numbers shown were 
obtained from 5 ng starting material (based on expected DNA quantity), pre-bisulfite 
conversion and RE digestion. RE dPCR data shows p14 copy number from the mock, MSRE 
and MDRE treatments. Methylight dPCR data shows copy number obtained using the p14_M 
assay in singleplex and the methylation independent control COL2A1. Statistical 
comparisons are for Student’s t-test (* = p < 0.05). Error bars show ± Standard Deviation of 
measurement. 
Bisulfite amplicon NGS 
To assess bisulfite amplicon NGS, sequencing experiments (n = 2 replicating the bisulfite, 
PCR and sequencing protocols) were performed using the Roche 454 GS Junior amplicon 
sequencing protocol on independent bisulfite conversions of the panel of 
methylated/unmethylated DNA. In order to quantify multiple samples in a single experiment, 
template DNA was PCR amplified using fusion primers containing MIDs. The assignment of 
MIDs to samples was randomised across the two experiments (Table 3). Two of the samples 
(25% and 50% methylated) were replicated within each experiment using different MID 
fusion primers in order to assess intra-run measurement repeatability. Figure 5A and B show 
strong correlations (p < 0.0001) between the expected and observed percent methylation 
values, both when averaging the observed percent methylation for all samples across both 
experiments (Figure 5A; R2 = 0.976) or when performing the correlation with individual data 
points (Figure 5B; R2; = 0.961). Although there was a strong correlation with the expected 
values, linear regression showed a clear trend for the bisulfite amplicon NGS to over-estimate 
the percent methylation (intercept of +8%, Figure 5A-B), evident in sample of mixed ratios 
by 1.32-fold on average. This effect was not observed in the 0% and 100% samples with less 
than 1% of reads not matching the expected sequence, resulting in non-random distribution of 
the residuals of the linear regression analysis (Additional file 3). The over-estimation bias had 
a greater impact for the lower percent methylation samples; for example, 10% methylation 
was over-estimated by 2.03-fold, whereas 90% methylation was over-estimated by 1.06-fold 
(Figure 5, Table 3). 
  
Table 3 Bisulfite amplicon NGS 
Run no. MID no. % methylation 
Expected (× replicate no.) Observed (× replicate no.) 
1 1 100 100 
2 90 96.4 
3 75 87.7 
9 50 × 1 85.3 
4 50 × 2 60.2 
7 50 × 3 64.3 
5 25 × 1 35.6 
10 25 × 2 38.7 
8 10 24.9 
6 0 0.2 
2 7 100 99.7 
3 90 94.8 
8 75 91.8 
9 50 × 1 84.5 
10 50 × 2 61.5 
6 50 × 3 74.5 
1 25 × 1 29.8 
4 25 × 2 28.2 
5 10 15.7 
2 0 0.6 
The % methylation determined by bisulfite amplicon NGS using Multiplex Identifier (MID) fusion primers to amplify 
samples from a panel of methylated/unmethylated DNA standards mixed in a range of known ratios. The 25% and 50% 
methylated samples were replicated (×1-3) within each of two runs. 
Figure 5 Bisulfite Amplicon NGS. Analysis showing read-based estimates of percent 
methylation (A-C). (A,B) Correlation between expected and observed percent methylation 
showing (A) average percent methylation for all samples across both amplicon NGS 
experiments or (B) all data points plotted individually excluding MID9 samples from the 
analysis in A and B. (C) Correlation between two bisulfite amplicon NGS experiments 
(including MID9). (D) Correlation between read- and site-based estimates of percent 
methylation. All correlations were significant at p < 0.0001. 
The correlation between experiments 1 and 2 was strong (Figure 5C; R2. = 0.987; p < 0.0001) 
suggesting a high level of reproducibility of the whole process. When comparing results from 
replicate samples with different MID fusion primers, however, one of the MID fusion primers 
(MID9) caused a clear bias in both experiments (Figure 5B) and therefore was removed from 
the correlation analysis (Figure 5A and B) (t-test showed that, for the 50% methylated 
sample, the MID9 values were significantly higher at p < 0.05 than the values excluding 
MID9). With the exception of the MID9-tagged amplicon, the difference in percent 
methylation between replicates (n = 2) ranged from 1% to 13%. The range of differences 
between replicates were similar when comparing within and between the two sequencing 
experiments, indicating that sources of variation within an experiment (e.g. different MID 
primers, independent PCRs) were the major sources of variability compared to factors 
differing between experiments (ie.g. bisulfite treatment, library preparation and sequencing). 
Figure 5D shows that there was a very strong correlation between the read- and site-based 
estimations of methylation indicating no measurable effect of PCR chimerism. 
Discussion 
DNA methylation status has been proposed as a biomarker for many diseases including 
cancer [6,7]. However, for the quantification of DNA methylation to be translated to clinical 
care, further work is needed to determine the accuracy of the available methods. In this study 
five methods were compared, comprising of two strategies to distinguish between methylated 
and unmethylated DNA (restriction digestion or bisulfite conversion), and three analytical 
platforms (qPCR, dPCR and NGS). 
Accuracy and precision of qPCR-based methods 
Of the qPCR methods tested, MethyLight qPCR demonstrated superior accuracy as reflected 
in good linearity over a wider range of % methylation compared to MSRE- or MDRE-based 
analyses which were optimal within the 0-50% and 50-100% methylation ranges respectively. 
This highlights the importance that both digestion strategies are applied when using this 
technique on samples of an unknown methylation status. However, MethyLight was also less 
accurate above 75% methylation. The MSRE/MDRE qPCR findings are consistent with 
Oakes et al. [23] which also identified a decreased accuracy of measurement in >75% 
methylated samples for MSRE and <25% for MDRE. This is likely due to difficulties in 
accurately discriminating between small differences between the sample and control (100% 
methylated DNA for MethyLight and MSRE qPCR and 0% methylated DNA for MDRE 
qPCR) by PCR, i.e. for RE qPCR analysis, a 10% difference translates to a difference in Cq 
of only 0.2, which is comparable to the typical standard deviation of Cq technical replicates. 
In addition, enzyme restriction or bisulfite conversion are sources of variability as the initial 
treatment of DNA can cause non-specific template degradation and confound the relative 
comparison between samples and control 100% methylated DNA [39]. 
The precision of both MethyLight- and RE-qPCR approaches was limiting in terms of 
discrimination between samples with small differences in methylation content. Our 
experiments demonstrated that the precision of Methylight measurements was sufficient to be 
able to discriminate differences of ≥25% methylation but not 10% or 15%, which is 
comparable with a previous study by Ogino et al. [40]. Both Methylight qPCR assay and 
bisulfite conversion were observed to contribute to overall technical error [40]. The precision 
of RE qPCR approaches measurement within their optimal ranges was comparable to 
Methylight qPCR, as statistical analysis revealed that differences in methylation of ≥25% 
could be reliably discriminated but not below this. 
Hashimoto et al. [24] reported that when using a MSRE qPCR approach with four 
independent replicate experiments, differences between two samples of 11% in methylation 
status could be determined, therefore increased replication may improve precision. Holemon 
et al. [25] found, when using a combined MDRE and MSRE qPCR approach, that the 
standard deviation measurements of replicate qPCR experiments were greater than that of 
replicate RE digestions. This further highlights how the number of replicate assays is as 
important a consideration when determining the confidence or uncertainty in the 
measurement, as both sample treatments (RE digestion or bisulfite conversion) and analysis 
stages contribute to the overall measurement variability. It is crucial that both stages are 
replicated in order to estimate the precision of measurements accurately. Control samples of 
defined methylation content such as those tested in this study may be a useful means of 
monitoring whole process precision. 
Application of dPCR to quantification of methylation 
Methylight has recently been applied to a dPCR platform [20], however its use for 
methylation quantification has not been extensively investigated; this study provides the first 
direct comparison of Methylight qPCR with Methylight dPCR and RE qPCR with RE dPCR. 
The correlation between qPCR and dPCR measurements for both upstream treatments was 
high (R2 ≥ 0.90), suggesting similar linearity to qPCR approaches. However, the precision of 
both Methylight and MSRE/MDRE-dPCR was found to be worse compared to the qPCR 
measurements. This is likely to be as a result of using a relatively low concentration of 
template (λ < 0.2 for all samples, Additional file 4) in order to be representative of typical 
clinical samples as our experiments were focussed on the application of methylation 
quantification to biomarker analysis. Based on Poisson statistics, dPCR is predicted to 
demonstrate highest precision at lambda values of between 1.0 and 2.0 [41]. Indeed, Hayden 
et al. [42] observed that dPCR showed higher measurement variability compared to qPCR 
when measuring human cytomegalovirus DNA in low concentration clinical samples. As in 
the Hayden et al. [42] report, the quantity of DNA analysed in our study by dPCR within the 
partitions of the IFC (0.65 ng) was lower than that analysed per qPCR reaction (5 ng). dPCR 
platforms with higher sample volume input and a greater number of partitions compared to 
the BioMark (such as the Bio-Rad Droplet Digital System and Life Technologies 
QuantStudio 3D Digital PCR System) may improve Methylight- or RE-based dPCR 
precision. 
Hayden et al. [42] observed that dPCR showed higher measurement variability compared to 
qPCR when measuring human cytomegalovirus DNA in low concentration clinical samples. 
As in the Hayden et al. [42] report, the quantity of DNA analyzed in our study by dPCR 
within the partitions of the IFC (0.65 ng) was lower than that analyzed per qPCR reaction (5 
ng). dPCR platforms with higher sample volume input and a greater number of partitions 
compared to the BioMark (such as the Bio-Rad Droplet Digital System and Life 
Technologies QuantStudio 3D Digital PCR System) may improve Methylight or RE-based 
dPCR precision. 
Absolute quantification of methylated DNA templates 
Our study extended the application of dPCR to analysis of DNA methylation by 
demonstrating how dPCR can be useful for studying the impact of upstream treatments on the 
number of amplifiable copies in a sample. Our dPCR experiments showed comparable p14 
DNA copy numbers in bisulfite-treated samples with those treated with REs or mock 
conditions. A previous study using an earlier bisulfite conversion protocol [39] demonstrated 
a loss of 84-96% of DNA after bisulfite treatment. Our study demonstrates that more recently 
developed protocols that use less harsh treatment conditions, may reduce sample loss 
significantly. However both Methylight and RE-based measurements were between 1.5- and 
2.3-fold lower than the copy number predicted by fluorimetric quantification, suggesting that 
additional sources of bias may reduce the number of amplifiable copies. 
We also developed a novel strategy for absolute quantification of methylated DNA by 
measuring both strands of the double helix post bisulfite-treatment. This method addresses an 
important source of uncertainty for dPCR-based quantification related to whether the 
template DNA is in single-stranded or double-stranded form [38]. Our data showing the 
location of the two strands of the double helix into separate partitions confirm the single-
stranded nature of the bisulfite converted DNA [13]. By quantifying all of the template 
strands in a reaction, this method provides an improvement for the absolute quantification of 
DNA copy number which could be particularly useful for the assignment of values to 
reference materials [38]. 
Accuracy and precision of bisulfite amplicon NGS method 
Bisulfite amplicon NGS using 454 pyrosequencing has been evaluated previously in analyses 
of clinical samples but has not been assessed in terms of its accuracy of measurement or 
directly compared against other technologies. The bisulfite amplicon NGS approach using the 
Roche Junior platform demonstrated superior precision compared to qPCR/dPCR methods, as 
evidenced by the high concordance of replicate experiments (R2 = 0.987). However the 
accuracy of bisulfite amplicon NGS was inferior to that of qPCR and dPCR as demonstrated 
by a systematic bias to over-estimate the percent methylation, with every observed value 
being above the expected, with the exception of the 0% and 100% methylated samples. On 
average, the measured values were 1.32-fold above the expected. It cannot be ruled out that 
the bias resulted from initial inaccuracy in template quantification and/or preparation prior to 
bisulfite amplicon NGS analysis. However, the same material was used for analysis by all of 
the other methodologies, none of which also showed a systematic over-estimation of 
methylation suggesting the bias was specific to this procedure. 
Our findings are also consistent with a previous study which found a pyrosequencing-based 
method to have a far superior precision of measurement compared to Methylight but it also 
demonstrated a systematic over-estimation in percent methylation [43]. However 
interrogation of passed and failed reads from the GS Junior sequencer revealed that these did 
not differ between the unmethylated vs. methylated sequences, suggesting that the bias did 
not stem from differences in the number of homopolymeric tracts in the sequences which 
may cause errors in pyrosequencing data due to the incorporation of multiple nucleotides in 
one flow [44]. 
It is more likely that the methylation bias was at the level of PCR as several previous studies 
have shown how bisulfite PCR, using methylation independent primers, can exhibit a strong 
methylation bias [45-47]. In these cases, however, the PCR bias results in an underestimation 
of methylation levels which was attributed to methylated DNA containing secondary 
structures in the template associated with a reduction in PCR efficiency compared to 
unmethylated sequences [45]. Other studies have observed a PCR-related bias towards 
methylated DNA: Dabney and Meyer found that certain DNA polymerases favour template 
molecules of higher GC content [48] while Shen et al. found that higher annealing 
temperatures increased the estimation of methylation content in samples of low to medium 
methylation (20-50%) [49], suggesting that changes in the choice of enzyme and/or annealing 
temperature may improve the bias observed in this study. 
In addition, our study demonstrates that there can be an interaction between sample identifier 
primer tags (MIDs) and PCR bias. One of the MID-tagged primers (MID9) showed 
methylation values that were clear outliers in both sequencing experiments: measurements of 
85% were observed for the 50% methylated sample compared to an average measurement of 
65.1% for other MID tags (Figure 5 and Table 3). A previous bacterial metagenomics study 
demonstrated that barcoded primers can introduce biases in PCR that translate into less 
reproducible data sets and can reduce apparent bacterial diversity, due to preferential 
amplification of certain 16S rRNA sequences [50]. This is also important for DNA 
methylation analysis as multiplexed amplicon sequencing is being applied to large-scale 
analysis of multiple methylation biomarkers [16,51]. In summary, further validation of the 
quantitative accuracy of deep sequencing is warranted, reinforcing the importance of 
reference controls to identify any biases that may be introduced. 
Conclusions 
Although previous investigations have discussed the relative merits of bisulfite conversion vs. 
RE digestion based methods of methylation quantification [18,24,25], this is the first study to 
directly compare both upstream treatments with alternative downstream PCR methods and 
platforms. Whilst MethyLight assays demonstrated an extended quantitative range compared 
to MSRE-or MDRE-qPCR, Methylight is a methylation specific PCR approach and is 
therefore limited to the CpGs that lie within the region that the primers and probes are 
designed to bind. In contrast, REs can be used that will target a larger number of methylation 
sites within a target region. Bisulfite amplicon NGS has the advantage over the other tested 
methods that it provides information on the methylation status of all CpG residues in an 
amplicon of the gene promoter that is larger than that of typical qPCR/dPCR assays; this 
technique displayed superior measurement precision compared to the others evaluated, 
however a systematic bias to over-estimate methylation rate was evident. These findings 
provide an important benchmark for these methods that assists researchers embarking on 
methylation studies to determine which method is most suitable for the purposes of their 
experiments and guide the aspects of these techniques that need to be addressed through the 
implementation of reference standards for methylation measurements. 
Methods 
Preparation of a panel of methylated/unmethylated DNA standards 
A panel of seven DNA standards was prepared by combining the following proportions of 
methylated and non-methylated Human DNA (Zymo Research, Irvine, CA, USA): 100%, 
90%, 75%, 50%, 25%, 10%, 0% methylated in 1.5 ml tubes at a final concentration of 20 
ng/µl. The commercially available Human DNA did not require approval by a Research 
Ethics Committee. DNA was diluted in TE buffer (10 mM Tris pH 8.0, 0.1 mM EDTA) 
(USB Corporation, Cleveland, OH, USA) and stored at −20°C. DNA was quantified using the 
Qubit 2.0 Fluorometer with the dsDNA BR Assay (Life Technologies, Carlsbad, CA, USA). 
RE digestion 
Three replicate RE digestions were performed on aliquots of a single preparation of the panel 
of methylated/unmethylated DNA standards. To encourage complete cleavage of the 
template, double digestions were performed for both the MS- and MDRE digestion reactions. 
For the MSRE reactions, AciI and HhaI were used, which contain a total of five potential 
cleavage sites in the p14 target region. For MDRE digestion, FspEI, which recognises seven 
potential methylated restriction sites, was used in combination with McrBC which cuts at 
multiple positions in methylated CpG rich sequences between two half-sites of the form 
(G/A)mC at an optimal distance of 55–103 bp. For each replicate, 3 × 10 µl RE digestion 
reactions were prepared for each sample: MSRE, MDRE and a mock digestion. All reaction 
components for the digestions were supplied by New England Biolabs (Ipswich, MA, USA). 
MSRE reactions contained: 1 × Buffer 3, 1 × Bovine Serum Albumin (BSA), 5 U AciI, 5 U 
HhaI and 100 ng DNA. MDRE reactions contained: 1 × Buffer 4, 1 × BSA, 1 × Enzyme 
Activator Solution, 1 × GTP, 5 U FspEI, 5 U McrBC and 100 ng DNA. Mock reactions 
contained 1 × Buffer 4 and 1 × BSA. Reactions were incubated at 37°C for 1 h and 
subsequently heat inactivated for 20 min at 65°C. Digests were diluted 1 in 10 with TE buffer 
(10 mM Tris pH 8.0, 0.1 mM EDTA) (USB Corporation) to 1 ng/µl for subsequent analysis 
and stored at −20°C. 
Sodium bisulfite treatment 
Three replicate sodium bisulfite conversion reactions were performed on the panel of 
methylated/unmethylated DNA standards using the EpiTect Plus Bisulfite Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions with 200 ng DNA and ethanol 
from Sigma (St. Louis, MO, USA). DNA was eluted from DNA spin columns in 15 µl and 
the volume made up to 50 µl with TE buffer (10 mM Tris pH 8.0, 0.1 mM EDTA) (USB 
Corporation). Reactions were performed on a GeneAmp 9700 thermocycler (Life 
Technologies). Samples were stored at −80°C. 
qPCR 
qPCR experiments (RE digestion qPCR and Methylight qPCR) were performed in 
accordance with the Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines (Additional file 5). Reactions were performed using 1 × 
Taqman Universal PCR mastermix, Cat no. 4304437 (Life Technologies) for RE digestion 
qPCR and 1 × Taqman Universal PCR mastermix without Uracil-DNA Glycosylase, Cat no. 
4324018 (Life Technologies) for Methylight qPCR in a final volume of 20 µl. All reactions 
also contained 900nM final concentration forward and reverse primers, 200nM Probes (see 
Additional file 6 for primer and probe sequences and Additional file 7 for details of assay 
performance) and 5 ng template DNA. All primers and probes were supplied by Sigma (UK). 
For RE qPCR, reactions contained 5 µl template DNA and Methylight qPCR contained 1.25 
µl DNA. Reactions were performed using a Prism 7900HT Real Time PCR system (Life 
Technologies). qPCR thermal cycling conditions were as follows: 95°C for 10 min, followed 
by 40 cycles of 95°C for 15 s, 60°C for 1 min. 
For RE digestion qPCR, all reactions were performed in triplicate. At least one PCR NTC 
was run for each assay as controls on all plates. The SDS software v2.4 (Life Technologies) 
was used to calculate the quantification cycle (Cq) value. For the RE qPCR assays, percent 
methylation was calculated by subtracting the mean Cq values of the MSRE or MDRE 
digested templates from the corresponding mock digest (∆Cq). ∆∆Cq was then calculated by 
subtracting the ∆Cq of the 100% methylated sample (MSRE digests) or the 0% (MDRE 
digests) from ∆Cq of the sample in question, and the equations 100 × (2∆∆Ct) and 100 × (1-
(2∆∆Ct)) were used to calculate % methylation respectively [52]. 
For Methylight qPCR, quantification was performed using the standard curve method with 
Bisulfite Converted Methylated Human DNA from Zymo Research. The standard curves 
consisted of 5 × 1 in 5 dilutions, the highest copy number being 7575 estimated haploid 
genome copies/reaction. For Methylight qPCR, standard curves were performed using 
triplicate measurements for each dilution and duplicates for the panel of 
methylated/unmethylated DNA standards. For Methylight qPCR, DNA copy number values 
were interpolated from standard curves and values for p14 were normalised to methylation 
independent COL2A1. Normalised copy numbers were then further normalised to the 100% 
methylated sample. 
Microfluidic dPCR 
Microfluidic dPCR experiments (Methylight dPCR and RE digestion dPCR) were performed 
in accordance with the Minimum Information for Publication of Digital Quantitative PCR 
Experiments (digital MIQE) guidelines (Additional file 8) using the Biomark system with 48 
panel “qdPCRTM 37 K” integrated fluidic circuits (IFCs), Cat. No. 100–6152 (Fluidigm, 
South San Francisco, CA, USA). Assays were performed using 1 × Taqman Universal PCR 
mastermix, Cat no. 4304437 (Life Technologies) for RE digestion dPCR and 1 × Taqman 
Universal PCR mastermix (no Uracil-DNA Glycosylase), Cat no. 4324018 (Life 
Technologies) for Methylight dPCR. All reactions also contained 2 × DA sample loading 
reagent, 900nM final concentration forward and reverse primers, 200nM Probes (see 
Additional file 2 for details of primer and probe design, Additional file 6 for primer and 
probe sequences, and Additional file 9 for assay performance) and 5 ng DNA. All primers 
and probes were supplied by Sigma (UK). For RE dPCR, 20 µl reactions containing 5 µl 
DNA were prepared and loaded across four panel inlets (5 µl per inlet) with the number of 
positive amplifications (counts) from the four panels being pooled together. For Methylight 
dPCR, 5 µl reactions containing 1.25 µl template DNA were loaded onto each panel inlet. 
dPCR thermal cycling conditions were as follows: 95°C for 10 min, followed by 45 cycles of 
95°C for 15 s, 60°C for 1 min. PCR NTCs were run as controls on all plates. The Fluidigm 
BioMark Data Collection software (version 4.0.1) was used to analyse the data. The number 
of positive amplifications (counts) was used for analysis of Cq variation, whereas the number 
of estimated targets (based on a Poisson correction of the proportion of positive partitions, to 
estimate the number of copies) was used for quantification of target copy number [53]. The 
average number of estimated molecules per chamber (lambda, λ) was calculated using the 
following equation: λ = − ln(1 − k/n) where k is the number of counts and n is the total 
number of partitions [54]. To calculate percent methylation for the RE digestion dPCR, 
estimated targets for the digestion reactions were normalised to those of the corresponding 
mock digest and further normalised to the 100% methylated sample for MSRE and 0% for 
the MDRE reactions to obtain %RQ. For the MDRE reactions, the final values were 
calculated using the equation 1 - %RQ. For Methylight dPCR, estimated targets for p14 
assays were normalised to those of the methylation independent COL2A1 assay. Normalised 
copy numbers were then further normalised to the 100% methylated sample. 
Bisulfite amplicon next generation sequencing 
Two replicate sample libraries were prepared from two independent bisulfite conversions and 
PCR amplifications of the methylated/unmethylated DNA standards (two of the three 
replicate bisulfite conversions that were also used for Methlight analysis) according to the 
standard Roche (Basel, Switzerland) GS Junior 454 protocol for amplicon sequencing 
(January 2013 version) using fusion primers where both the forward and reverse primers 
contain the Roche adapter sequences and the forward primers also contain a Multiplex 
Identifier (MID) to enable sequencing reads to be assigned to each sample (see Additional 
file 6 for fusion primer sequences). Two of the samples (25% and 50% methylated) were 
replicated in each library preparation (25%, n = 2; 50%, n = 3) using different MID fusion 
primers. The assignment of MID fusion primers to samples was randomised in each library 
preparation (Table 3). Amplicon libraries were generated using the Roche FastStart High 
Fidelity PCR System according to the manufacturer’s protocol using 20 ng template DNA 
and the following cycling parameters: 94°C for 3 min, 35 cycles of 94°C for 15 s, 60°C for 
45 s, 72°C for 60 s followed by an incubation at 72°C for 8 min. After purification, libraries 
were quantified using the Qubit 2.0 Fluorometer (Life Technologies) to estimate DNA copy 
number and analysed with the Agilent Bioanalyzer 2100 to verify product size. Amplicon 
libraries were combined in an equimolar ratio, using 1 × 107 DNA molecules with 5 × 106 
beads (2 to 1 ratio) for emulsion PCR. Two sequencing experiments were performed on the 
replicate library preparations using the Roche GS Junior Titanium emulsion PCR (Lib-A), 
Sequencing and PicoTiterPlate Kits according to the manufacturer’s protocols on a Roche GS 
Junior sequencer. 
Sequencing data analysis 
Sequence reads were aligned (Exonerate, version 2.2.0, with options model = affine:local and 
subopt = F, score = 600) to a 205 nucleotide template p14 reference sequence in which all 
cytosine residues were masked. Masking avoided bias in alignment between bisulfite 
modified and un-modified sequences. As a stringent quality filter, only reads with >90% 
identity (excepting bisulfite modifiable sites) and >90% coverage to the reference sequence 
were considered for further analysis. Pairwise alignments were used to construct reference 
sequenced anchored multiple read alignments by preserving alignment gaps in the sequence 
read but removing alignment gap-columns in the reference sequence. At each methylation 
informative site (C of the CpG in the unmodified template) the fraction of bisulfite non-
conversion (Ccount/(Ccount + Tcount)) were scored across all reads. The mean of the 
methylation rate over the 19 informative sites provided a “site based estimate” (SBE) of 
methylation for each sample. As a complementary approach we also produced a “read based 
estimate” (RBE) of methylation by categorising each sequence read based on the fraction of 
bisulfite converted informative sites: methylated (<=20%), indeterminate (>20%, <80%) or 
unmethylated (> = 80%). The RBE for the sample was calculated as the fraction 
methylated/(methylated + unmethylated) ignoring indeterminate classification reads. In these 
datasets the fraction of indeterminate reads was always <1%. Sequence and alignment 
manipulation was implemented in Perl (version 5.10.1), quantization and analysis in R 
(version 3.0.0). 
Statistical analysis 
Statistical analysis was performed using Graphpad Prism version 5.04 (GraphPad). All data 
sets showed a normal distribution, passing the Kolmogorov-Smirnov normality test at α = 
0.05. One-way Analysis of Variance (ANOVA) comparing observed percent methylation 
values between different samples within the constructed panel was performed with the 
Tukey’s Multiple Comparison post-hoc test. Correlation analysis was performed using a two-
way Pearson correlation. 
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